このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery (TANAMI)

2026年9月7日 更新者:Gregor Reiter、Medical University of Vienna

Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery in a Prospective Randomized Controlled Inter-eye Study

Dry eye disease can occur or worsen after cataract surgery and may cause ocular discomfort and reduced visual quality. Standard treatment commonly includes artificial tear eye drops, which provide temporary lubrication. Temporary occlusion of the tear drainage system may offer an alternative approach by increasing tear retention and improving tear film stability.

This prospective, randomized, double-blind, inter-eye study will evaluate the use of LACRIFILL® Canalicular Gel, a crosslinked hyaluronic acid gel placed in the tear drainage system, in patients who have undergone bilateral cataract surgery. Treatment allocation will be randomized at the eye level within each participant. One eye will be assigned to treatment with LACRIFILL®, while the fellow eye will serve as the control and receive standard care with artificial tear eye drops.

The study will compare the development and severity of dry eye disease between the randomized treatment and control eyes. The main outcome will be tear production measured by the Schirmer Test 1 one month after treatment. Additional assessments will include tear film stability, ocular surface findings, anterior segment imaging, visual quality, dry eye symptoms, use of artificial tears, and treatment-related safety outcomes during a three-month follow-up period.

調査の概要

状態

まだ募集していません

条件

介入・治療

研究の種類

介入

入学 (推定)

25

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • State of Vienna
      • Vienna、State of Vienna、オーストリア、1090
        • Medical University of Vienna, Department of Ophthalmology and Optometry
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Gregor S. Reiter, MD, PhD, BA, MSc
        • 副調査官:
          • Johannes Schrittwieser, MD
        • 副調査官:
          • Markus Schranz, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Uncomplicated bilateral cataract surgery for age-related cataract within the last 2-7 days
  • Implantation of the same type of lens in both eyes (diopters may differ).
  • Age 45-99 years
  • Willingness to complete the study
  • Signed informed consent form

Exclusion Criteria:

  • Bilateral cataract due to a different cause
  • Retinal findings affecting quality of life or visual acuity in any eye
  • History of uncontrolled glaucoma in any eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation)
  • Active or suspected ocular or periocular infection in the study eye.
  • Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:LACRIFILL® Canalicular Gel Lacrimal Occlusion
Within each participant, one eye will be randomly assigned to receive a single intracanalicular administration of LACRIFILL® Canalicular Gel into the lower canaliculus. The intervention is intended to provide temporary occlusion of the lacrimal drainage system and thereby reduce tear drainage and increase tear retention. The fellow eye will serve as the control eye.
LACRIFILL® Canalicular Gel is a crosslinked hyaluronic acid hydrogel administered intracanalicularly into the lower canaliculus. Approximately 0.2 mL is administered as a single application to the randomized treatment eye to achieve temporary occlusion of the lacrimal drainage system.
偽コンパレータ:Lacrimal Irrigation
The fellow eye of each participant will undergo lacrimal irrigation as a sham procedure. No LACRIFILL® Canalicular Gel will be administered to the control eye. The control eye will otherwise receive standard postoperative care, including artificial tear supplementation, according to standard clinical practice.
Lacrimal irrigation performed as a sham procedure in the control eye without administration of LACRIFILL® Canalicular Gel or temporary canalicular occlusion.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Inter-eye difference in Schirmer Test 1 at month 1
時間枠:1 months
Difference in Schirmer Test I tear production between the Lacrifill-treated eye and the contralateral standard-of-care eye at 1 month after cataract surgery. Schirmer Test I measures tear production as the length of wetting of a standardized filter paper strip over 5 minutes, expressed in millimeters (mm). Values for each eye range from 0 to 35 mm, with higher values indicating greater tear production. The inter-eye difference is calculated as the Schirmer Test I value in the Lacrifill-treated eye minus the value in the standard-of-care eye, resulting in a possible range of -35 to +35 mm. Positive values indicate greater tear production in the Lacrifill-treated eye.
1 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Inter-eye difference in Schirmers Test 1 at month 3
時間枠:3 Months
Difference in Schirmer Test I tear production between the Lacrifill-treated eye and the contralateral standard-of-care eye at 3 month after cataract surgery. Schirmer Test I measures tear production as the length of wetting of a standardized filter paper strip over 5 minutes, expressed in millimeters (mm). Values for each eye range from 0 to 35 mm, with higher values indicating greater tear production. The inter-eye difference is calculated as the Schirmer Test I value in the Lacrifill-treated eye minus the value in the standard-of-care eye, resulting in a possible range of -35 to +35 mm. Positive values indicate greater tear production in the Lacrifill-treated eye.
3 Months
Inter-eye difference in Oxford grading at month 1 and months 3
時間枠:1 month, 3 months
Difference in ocular surface staining between the Lacrifill-treated eye and the contralateral standard-of-care eye at 1 and 3 months after cataract surgery, assessed using the Oxford Scheme for Ocular Surface Staining. The Oxford score ranges from 0 to 5 for each eye, with higher scores indicating greater ocular surface staining and therefore a worse outcome. The inter-eye difference is calculated as the Oxford score in the Lacrifill-treated eye minus the score in the standard-of-care eye, resulting in a possible range of -5 to +5. Negative values indicate less ocular surface staining, and therefore a better outcome, in the Lacrifill-treated eye.
1 month, 3 months
Inter-eye difference in tear break up time (TBUT) at month 1 and 3
時間枠:1 month; 3 months
Difference in Tear Film Break-Up Time (TBUT) between the Lacrifill-treated eye and the contralateral standard-of-care eye at 1 and 3 months after cataract surgery. TBUT is measured in seconds and represents the time between a complete blink and the first appearance of a break in the tear film. Higher TBUT values indicate greater tear film stability and therefore a better outcome. The inter-eye difference is calculated as the TBUT in the Lacrifill-treated eye minus the TBUT in the standard-of-care eye; positive values indicate greater tear film stability in the Lacrifill-treated eye.
1 month; 3 months
Non-invasive tear break-up time measured with the MS-39 at Months 1 and 3
時間枠:1 month; 3 months
Tear film stability will be assessed using the first non-invasive tear break-up time (NIBUT) measured with the MS-39 anterior segment analyzer (CSO, Florence, Italy). The integrated Placido disk-based tear film analysis detects the time from the last blink to the first detected disruption of the tear film. NIBUT is recorded in seconds. Higher values indicate greater tear film stability and therefore a better outcome. Measurements will be performed separately in the Lacrifill-treated eye and the contralateral sham-treated eye.
1 month; 3 months
Halo/glare size measured with the Real Artificial Lens Vision (RALV) system
時間枠:1 month and 3 months
Halo/glare size will be quantitatively assessed using the Real Artificial Lens Vision (RALV) halo/glare test. Participants view a central white light source while optotypes are presented at decreasing radial distances from the light source. Halo/glare size is recorded as angular extent in milliradians (mrad). Higher values indicate a larger halo/glare phenomenon and therefore greater visual disturbance. Measurements will be performed separately for the Lacrifill-treated eye and the contralateral sham-treated eye.
1 month and 3 months
Outcomes of questionnaires
時間枠:1 month; 3 months
Report of the dry eye disease questionnaires (OSDI and SPEED) and the National Eye Institute Visual function questionnaire 25 at month 1 and 3
1 month; 3 months
Number of applied artifical tear drops
時間枠:3 months
Self-reported number of average applications of artificial tear drops per eye per day.
3 months
Incidence of adverse events and device- or procedure-related adverse events
時間枠:3 months
Incidence, nature, severity, and relationship to the investigational device and/or procedure of adverse events, including serious adverse events and serious adverse device effects.
3 months
Inter-eye difference in visual quality assessment
時間枠:1 month; 3 months
Difference in Visual quality assessment measured by Refractive Artificial Lens Vision (RALV) at month 1 and 3
1 month; 3 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月15日

一次修了 (推定)

2027年10月1日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2026年8月31日

QC基準を満たした最初の提出物

2026年9月7日

最初の投稿 (実際)

2026年9月9日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月9日

QC基準を満たした最後の更新が送信されました

2026年9月7日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 1058/2026

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。